Cambridge, MA – September 19, 2016 – Neon Therapeutics, an immuno-oncology company developing neoantigen-based therapeutic vaccines and T cell therapies to treat cancer, today announced that it has been named by FierceBiotech as one of 2016’s Fierce 15 biotechnology companies, recognizing it as one of the most promising private biotechnology companies in the industry.
Founded by seven world-recognized leaders in immuno-oncology, Neon Therapeutics announced its launch in October 2015 with a $55 million Series A financing from Third Rock, Clal Biotechnology Industries and Access Industries. Neon’s long-term vision is to develop the next generation of cancer immunotherapy treatments through the development of multiple programs in therapeutic vaccines and T cell modalities, targeting both neoantigens that are specific to individual patients as well as neoantigens that are shared across patients and tumor types.
“At Neon Therapeutics, we are committed to advancing the field of cancer immunotherapy by taking full advantage of neoantigen biology to bring cancer treatments to patients in need,” said Cary Pfeffer, M.D., interim chief executive officer of Neon Therapeutics. “As we approach the anniversary of our launch, we recognize the enormous strides our team has made in developing our product pipeline and the productive collaborations we have established with leading academic institutions and industry partners. It is a tremendous honor that our approach and the hard work by our team are recognized through this Fierce 15 designation.”
About Fierce 15
The Fierce 15 celebrates the spirit of being “fierce” – championing innovation and creativity, even in the face of intense competition. This is FierceBiotech’s fourteenth annual Fierce 15 selection.
An internationally recognized daily report reaching a network of over 300,000 biotech and pharma industry professionals, FierceBiotech provides subscribers with an authoritative analysis of the day’s top stories. Every year FierceBiotech evaluates hundreds of private companies from around the world for its annual Fierce 15 list, which is based on a variety of factors such as the strength of its technology, partnerships, venture backers and a competitive market position.
FierceBiotech is the biotech industry’s daily monitor, an email newsletter and web resource providing the latest biotech news, articles, and resources related to clinical trials, drug discovery, FDA approval, FDA regulation, patent news, pharma news, biotech company news and more. More than 160,000 top biotech professionals rely on FierceBiotech for an insider briefing on the day’s top stories. Signup is free at www.fiercebiotech.com/signup.
About Neon Therapeutics
Neon Therapeutics is an immuno-oncology company focused on developing novel therapeutics leveraging neoantigen biology to treat cancer. A neoantigen-based product engine allows Neon to develop multiple treatment modalities, including next-generation vaccines and T cell therapies targeting both personalized and shared neoantigens. Neon’s lead program is a personalized neoantigen vaccine that builds upon years of research and development at the Broad Institute and Dana-Farber Cancer Institute, and is already in multiple clinical trials. For more information, please visit www.neontherapeutics.com.
Ten Bridge Communications, Inc.